Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies (Q44646864)

5 December 2017

title

Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies (English)

1 reference

5 December 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

29 March 2024

2

Dennis R Burton

1 reference

5 December 2017

Ralph Pantophlet

1

1 reference

5 December 2017

language of work or name

1 reference

1 November 2003

1 reference

full work available at URL

5 December 2017

https://api.elsevier.com/content/article/PII:S147149140300193X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

https://api.elsevier.com/content/article/PII:S147149140300193X?httpAccept=text/plain

29 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Trends in Molecular Medicine

29 March 2024

published in

1 reference

5 December 2017

volume

9

1 reference

5 December 2017

issue

11

1 reference

5 December 2017

page(s)

468-473

1 reference

Cellular immune responses to HIV.

5 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

29 March 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys

29 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus

29 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.

29 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

29 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

29 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

29 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

29 March 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

29 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

29 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

The antigenic structure of the HIV gp120 envelope glycoprotein

29 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

29 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

29 March 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

29 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus

29 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

29 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

29 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins

29 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

29 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

29 March 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates

29 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response

29 March 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response

29 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

29 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

29 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

29 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials

29 March 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

29 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus

29 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

29 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

29 March 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design

29 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Can epitope-focused vaccines select advantageous immune responses?

29 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Refocusing of B-cell responses following a single amino acid substitution in an antigen

29 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Neutralizing antibodies against HIV -- back in the major leagues?

29 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

29 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

29 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion

29 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

29 March 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

29 March 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

29 March 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

29 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs

29 March 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells

29 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.MOLMED.2003.09.001

29 March 2024

Identifiers

1 reference

5 December 2017

1 reference